Skip to main content
Contact Us
Subscribe
E-Edition
35°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Avrobio Inc
(NQ:
AVRO
)
1.400
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Avrobio Inc
< Previous
1
2
3
Next >
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
September 14, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Participate in Four Upcoming Investor Conferences in September
August 31, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Participate in Two Upcoming Investor Conferences in August
August 01, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
July 13, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2022
From
AVROBIO
Via
Business Wire
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 18, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
May 17, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
From
AVROBIO
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
May 03, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
March 17, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
February 09, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
February 01, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
January 28, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
January 27, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reprioritizes Pipeline Programs
January 04, 2022
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2021
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
November 24, 2021
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present at Two Upcoming Investor Conferences in November
November 09, 2021
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
November 08, 2021
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From
AVROBIO, Inc.
Via
Business Wire
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021
From
AVROBIO, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.